488 related articles for article (PubMed ID: 21805188)
1. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
3. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
4. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.
Gomes-da-Silva LC; Santos AO; Bimbo LM; Moura V; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Int J Pharm; 2012 Sep; 434(1-2):9-19. PubMed ID: 22617794
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
6. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
7. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
8. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
[TBL] [Abstract][Full Text] [Related]
10. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo.
Bandekar A; Zhu C; Gomez A; Menzenski MZ; Sempkowski M; Sofou S
Mol Pharm; 2013 Jan; 10(1):152-60. PubMed ID: 23134440
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer.
Dong D; Gao W; Liu Y; Qi XR
Cancer Lett; 2015 Apr; 359(2):178-86. PubMed ID: 25592040
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo.
Obata Y; Tajima S; Takeoka S
J Control Release; 2010 Mar; 142(2):267-76. PubMed ID: 19861141
[TBL] [Abstract][Full Text] [Related]
13. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth.
Wang Z; Yu Y; Dai W; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2013 Jan; 34(3):756-64. PubMed ID: 23117217
[TBL] [Abstract][Full Text] [Related]
14. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery.
Jiang T; Zhang Z; Zhang Y; Lv H; Zhou J; Li C; Hou L; Zhang Q
Biomaterials; 2012 Dec; 33(36):9246-58. PubMed ID: 23031530
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
16. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer.
Wang Z; Yu Y; Dai W; Lu J; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2012 Nov; 33(33):8451-60. PubMed ID: 22940213
[TBL] [Abstract][Full Text] [Related]
17. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
[TBL] [Abstract][Full Text] [Related]
18. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.
Herringson TP; Altin JG
J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652
[TBL] [Abstract][Full Text] [Related]
19. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
Hu FQ; Zhang YY; You J; Yuan H; Du YZ
Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
[TBL] [Abstract][Full Text] [Related]
20. Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin.
Rivera-Fillat MP; Reig F; Martínez EM; Grau-Oliete MR
J Pept Sci; 2010 Jul; 16(7):315-21. PubMed ID: 20552567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
